Summary The International Initiative on Thrombosis and Cancer is an independent
academic working group of experts aimed at establishing global consensus for the treatment …

Acute lymphoblastic leukemia (ALL) is a malignancy of lymphoid progenitor cells occurring
at an annual incidence rate of approximately 1.1–2.1 per 100,000 person-years globally …

Anticoagulation in children is problematic for multiple reasons. Currently used
anticoagulants have significant disadvantages and may negatively affect quality of life …

Adolescents and young adults (AYAs) with acute lymphoblastic leukemia have improved
outcomes when treated with pediatric-inspired regimens. CALGB 10403 was the largest …

Administering asparaginase has always been problematic in adults because most general
oncologists who treat adults are not familiar with its usage and toxicity. The toxicity profile of …

Venous thromboembolic (VTE) complications in children and adolescents with acute
lymphoblastic leukaemia (ALL) and T or B cell lymphoblastic lymphoma (T/B cell LL) can …

Patients undergoing treatment of acute lymphoblastic leukemia (ALL) are at risk for
thrombosis, caused in part by the use of l-asparaginase (L-ASP). Antithrombin (AT) …

With recent prospective clinical trials that used paediatric regimens with multiple doses of
pegylated form of asparaginase (PEG asparaginase) in adults reporting significantly …

Insufficient exposure to asparaginase therapy is a barrier to optimal treatment and survival in
childhood acute lymphoblastic leukaemia (ALL). Three important reasons for inactivity or …

Venous thromboembolism is a common complication of asparaginase‐based chemotherapy
regimens for the treatment of acute lymphoblastic leukemia. Thrombosis associated with …